Prostate Cancer Therapies
Research activity includes treatment strategies for metastatic hormone-sensitive prostate cancer with high tumor load and metastatic castration-resistant prostate cancer, with attention to disease control and progression outcomes in advanced prostate malignancy.
- Androgen deprivation therapy combinations
- Metastatic hormone-sensitive prostate cancer
- Metastatic castration-resistant prostate cancer
The sponsor’s oncology portfolio reflects a strong focus on advanced prostate cancer settings, including both hormone-sensitive and resistant disease states.
Targeted Oncology and DNA Repair-Related Treatment
Clinical research also covers PARP inhibitor-based approaches in metastatic castration-resistant prostate cancer, including patients selected by DNA repair deficiency status and broader unselected populations.
- PARP inhibition
- DNA repair deficiency
- Combination therapy in advanced cancer
This area links molecularly informed treatment concepts with late-stage oncology care.
Supportive Care in Chemotherapy
Another therapeutic interest is the management of chemotherapy-induced thrombocytopenia, focusing on restoration of platelet count in patients affected by treatment-related blood toxicity.
- Chemotherapy-induced thrombocytopenia
- Thrombocytopenia management
- Hematologic supportive care
These studies place emphasis on maintaining treatment continuity in patients receiving cancer therapy.
Clinical Pharmacology and Global Oncology Development
Research activity extends across multiple active sites and countries, with interest in pharmacokinetics and treatment use in diverse patient populations outside Asia, alongside multinational development in oncology and hematology.
- Pharmacokinetic evaluation
- International trial participation
- Multicountry oncology research
The sponsor’s trial portfolio spans advanced cancer treatment and supportive hematologic care.
